Analysts Are Bullish on These Healthcare Stocks: Aethlon Medical Inc (AEMD), Quidel Corp (QDEL)


There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aethlon Medical Inc (AEMD), Quidel Corp (QDEL) and DBV Technologies SA – American (DBVT) with bullish sentiments.

Aethlon Medical Inc (AEMD)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aethlon Medical Inc today and set a price target of $3. The company’s shares closed yesterday at $0.94, close to its 52-week low of $0.82.

Selvaraju wrote:

“Our 12-month price target is derived from a market value of the firm at $80M, which includes a discounted cash flow-based asset value of $81M for the Hemopurifier, using a 15% discount rate and 0% terminal growth rate, with 40% probability of success and excluding $1M debt.”

According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -9.8% and a 32.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Currently, the analyst consensus on Aethlon Medical Inc is a Moderate Buy with an average price target of $3.

See today’s analyst top recommended stocks >>

Quidel Corp (QDEL)

Canaccord Genuity analyst Mark Massaro maintained a Buy rating on Quidel Corp today and set a price target of $72. The company’s shares closed yesterday at $61.13.

Massaro noted:

“We believe the QDEL management team is rejuvenated and firing on all cylinders, and never before in its history has had such a deep and broad-based new product pipeline, which we believe will enable the company to execute nicely against Street expectations. While the stock has recovered from its December sell-off related to the Beckman legal matter, we see further upside from here as we believe the Beckman matter “works itself out” with little damage (perhaps with a settlement, at the worst). We reiterate QDEL as one of our top picks for 2019, modestly raise our estimates, and raise our price target to $72 (from $70).”

According to TipRanks.com, Massaro is a 5-star analyst with an average return of 15.9% and a 57.3% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Meridian Bioscience Inc, Quanterix Corporation, and Orasure Technologies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Quidel Corp with a $68.20 average price target.

DBV Technologies SA – American (DBVT)

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on DBV Technologies SA – American today and set a price target of $25. The company’s shares closed yesterday at $7.05, close to its 52-week low of $3.60.

Fein wrote:

“Our $25/share price target is based on an equally weighted composite of: (a) $27/ share, as a 20x multiple of taxed and diluted FY25 GAAP EPS of $8.20 discounted back to and (b) an NPV of $22/share (discount rate 12.5%, growth rate 2.5%). Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition, and pricing.”

According to TipRanks.com, Fein is a 4-star analyst with an average return of 6.8% and a 44.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Proteostasis Therapeutics Inc, and Eloxx Pharmaceuticals Inc.

The word on The Street in general, suggests a Hold analyst consensus rating for DBV Technologies SA – American with a $11.67 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts